Stock ACAD ACADIA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company ACADIA Pharmaceuticals Inc.

Equities

ACAD

US0042251084

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 10:57:54 2024-04-25 am EDT 		5-day change 1st Jan Change
16.34 USD -1.48% Intraday chart for ACADIA Pharmaceuticals Inc. -4.04% -47.68%
Apr. 23 Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada MT
Apr. 22 Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada MT

Business Summary

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

Number of employees: 598

Sales per Business

USD in Million2022Weight2023Weight Delta
Innovative Medicines
100.0 %
517 100.0 % 726 100.0 % +40.45%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
517 100.0 % 726 100.0 % +40.45%

Managers

Managers TitleAgeSince
Stephen Davis CEO
 Chief Executive Officer 63 14-07-14
Mark Schneyer DFI
 Director of Finance/CFO 50 20-05-27
Sanjeev Pathak CTO
 Chief Tech/Sci/R&D Officer - 21-02-28
Douglas Williamson CTO
 Chief Tech/Sci/R&D Officer 61 23-01-08
Brendan Teehan COO
 Chief Operating Officer 56 18-06-30
Ponni Subbiah CTO
 Chief Tech/Sci/R&D Officer - 19-09-30
Benir Ruano CTO
 Chief Tech/Sci/R&D Officer - 22-10-31
Albert Kildani
- -
Holly Valdiviez SAM
 Sales & Marketing - 22-03-31
Rob Ackles HRO
 Human Resources Officer - 13-12-31

Members of the board

Members of the board TitleAgeSince
Julian Baker BRD
 Director/Board Member 57 15-12-10
Edmund Harrigan BRD
 Director/Board Member 71 15-11-24
Stephen Davis CEO
 Chief Executive Officer 63 14-07-14
Don Soland BRD
 Director/Board Member 65 15-03-19
Laura Brege BRD
 Director/Board Member 66 08-04-30
Stephen Biggar CHM
 Chairman 53 13-01-21
James Daly BRD
 Director/Board Member 63 16-01-10
Elizabeth Garofalo BRD
 Director/Board Member 66 20-09-28
Adora Ndu BRD
 Director/Board Member 43 22-10-09

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 164,771,521 163,859,371 ( 99.45 %) 0 99.45 %

Shareholders

NameEquities%Valuation
Baker Bros. Advisors LP
26.01 %
42,864,612 26.01 % 793 M $
Vanguard Fiduciary Trust Co.
8.130 %
13,396,009 8.130 % 248 M $
RTW Investments LP
6.830 %
11,253,551 6.830 % 208 M $
BlackRock Advisors LLC
6.316 %
10,406,712 6.316 % 192 M $
STATE STREET CORPORATION
3.924 %
6,465,026 3.924 % 120 M $
EcoR1 Capital, LLC
3.636 %
5,991,479 3.636 % 111 M $
Fidelity Management & Research Co. LLC
3.196 %
5,265,358 3.196 % 97 M $
T. Rowe Price International Ltd.
3.143 %
5,178,509 3.143 % 96 M $
D.E. Shaw & Co., Inc.
2.279 %
3,754,598 2.279 % 69 M $
Weatherbie Capital LLC
1.928 %
3,176,775 1.928 % 59 M $

Company contact information

ACADIA Pharmaceuticals, Inc.

12830 El Camino Real Suite 400

92130-3331, San Diego

+858 558 2871

http://www.acadia.com
address ACADIA Pharmaceuticals Inc.(ACAD)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for ACADIA Pharmaceuticals Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
16.59 USD
Average target price
29.09 USD
Spread / Average Target
+75.37%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ACADIA PHARMACEUTICALS INC. Stock ACADIA Pharmaceuticals Inc.
-47.68% 2.73B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.92% 43.84B
MODERNA, INC. Stock Moderna, Inc.
+5.63% 41.68B
LONZA GROUP AG Stock Lonza Group AG
+45.26% 41.25B
CELLTRION, INC. Stock Celltrion, Inc.
-10.92% 27.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.81% 25.53B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.62% 18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.69% 12.29B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+24.69% 12.29B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.86% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ACAD Stock
  4. Company ACADIA Pharmaceuticals Inc.